News Headlines

Display #
New Data Reveals This New York Biotech’s Pipeline Could be a Game Changer
Sanofi chief says U.S. Supreme Court ruling on biologics has “immediate impact”
Exercise may stave off postpartum depression
FCB’s Area 23 Named “Healthcare Agency of the Year” at 2017 Cannes Lions Health Festival
Lions Health 2017: Health & Wellness Winners
Lions Health 2017: Pharma Winners
New patient survey highlights need for more action to help severe asthma patients gain control of their disease
Google backs new European biotech drug fund
Tresiba® demonstrated no increased risk of major cardiovascular events and significant reduction in rates of severe hypoglycaemia compared to insulin glargine U100 in the DEVOTE trial
New Biotech Incubator Opened Up in the Big Apple – With Room for 25 Startups
Disappointing Phase II Data for Epizyme drug
Senate may keep some Obamacare taxes in U.S. healthcare overhaul
EULAR 2017: Lilly’s Taltz (ixekizumab) Demonstrated Significant Improvements in Disease Signs and Symptoms at 24 Weeks Among Patients with Active Psoriatic Arthritis Who Had Prior Inadequate Response or Intolerance to TNF Inhibitors
UK will pay for Roche breast cancer drug
FDA Voice Blog: Fostering Medical Innovation – A Plan for Digital Health Devices
Targeting immune cells that help tumors stay hidden could improve immunotherapy
Bristol-Myers Squibb to sell manufacturing facility in Swords, Ireland to SK Biotek Co., Ltd.
Pfizer, Roche and Aspen face South Africa probe over cancer drug prices
Centene to expand Obamacare insurance to three new states in 2018
FDA delays rolling out new nutrition facts label
Centrexion’s chili-based painkiller offers relief for 6 months – study
Roche's employee-driven philanthropic campaign sets new record
Sanofi Commits $673 Million in Biologics
Study shows pharmacists knew more about penicillin allergy than MDs
BioTime’s Renevia succeeds in pivotal European facial wasting trial
Boehringer Ingelheim presents phase III results demonstrating clinical equivalence of adalimumab biosimilar candidate to Humira
J&J’s flu drug succeeds in mid-stage trial
Janssen Presents Long Term Phase 3 Efficacy and Safety Data of Sirukumab in Rheumatoid Arthritis Patients Who had an Inadequate Response and/or Who Were Intolerant to Anti-TNFs
Boehringer Ingelheim builds Digital Lab "BI X" with focus on innovative digital solutions in healthcare
Bayer Grants4Apps® Dealmaker Berlin 2017